Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Longitudinal ctdna tracking by low-pass whole-genome sequencing during CD19 CAR-T cell therapy for B-cell lymphomas

Sijun Zhang, Honghan Qiao, Yaqing Li, Feiyang zong, Yukai Duan, Renjie Hua, Qingjiang Chen, Mingzhi Zhang, Xudong Zhang

Blood (2025) 146 (Supplement 1): 7060.

https://doi.org/10.1182/blood-2025-7060

Published: 2025

Journal Articles

Tumor-associated macrophages (CD68+) as a potential prognostic biomarker for PD-1 inhibitor response in relapsed/refractory classical Hodgkin lymphoma

Shiji Wang, Jie Wang, Mingzhi Zhang, Xudong Zhang, Hui Yu

Blood (2025) 146 (Supplement 1): 7137.

https://doi.org/10.1182/blood-2025-7137

Published: 2025

Journal Articles

Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors

Jieming Zhang, Mengjie Ding, Feifei Nan, Xiaorui Fu, Yu Chang, Lei Zhang, Mingzhi Zhang, Xudong Zhang

Blood (2025) 146 (Supplement 1): 8015.

https://doi.org/10.1182/blood-2025-8015

Published: 2025

Journal Articles

Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis

Jie Wang, Mengke Huang, Yukai Duan, Shiji Wang, Xudong Zhang, Mingzhi Zhang, Hui Yu

Blood (2025) 146 (Supplement 1): 3741.

https://doi.org/10.1182/blood-2025-3741

Published: 2025

Journal Articles

Selinexor combined with pegaspargase and dexamethasone, followed by radiotherapy, for newly diagnosed stage I–II natural killer/T-cell lymphoma: A multicenter, single-arm, Phase I/II study

Siyu Qian, Yue Zhang, Mingzhi Zhang, Xudong Zhang

Blood (2025) 146 (Supplement 1): 5429.

https://doi.org/10.1182/blood-2025-5429

Published: 2025

Journal Articles

Orelabrutinib plus anti-PD-1 antibody and fotemustine for newly diagnosed primary central nervous system lymphoma: Phase I/II results

Wanyue Zhao, Mengke Fan, Shanshan Ma, Mingzhi Zhang, Xudong Zhang

Blood (2025) 146 (Supplement 1): 5465.

https://doi.org/10.1182/blood-2025-5465

Published: 2025

Journal Articles

Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China

Honghan Qiao, Xingchen Liu, Huijie Nan, Mingzhi Zhang, Yanliang Bai, Keshu Zhou, Xudong Zhang

Blood (2025) 146 (Supplement 1): 7206.

https://doi.org/10.1182/blood-2025-7206

Published: 2025

Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Blood (2025) 146 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2025-3689

Published: 2025

Journal Articles

Oligocentric castleman disease: Clinical characteristics and surgical outcomes from a single-centre retrospective study

Yukai Duan, Xudong Zhang, Mingzhi Zhang

Blood (2025) 146 (Supplement 1): 6572.

https://doi.org/10.1182/blood-2025-6572

Published: 2025

Journal Articles

POD 12 As a Robust Prognostic Index in Patients with Angioimmunoblastic T-Cell Lymphoma: A Single-Center Study

Suxiao Li, Xiaoyan Feng, Jieming Zhang, Yunfei Song, Mengke Fan, Qingjiang Chen, Mingzhi Zhang, Xiaolong Wu, Meng Dong, Lijuan Han, Xudong Zhang

Blood (2024) 144 (Supplement 1): 6410.

https://doi.org/10.1182/blood-2024-207198

Published: 2024

Journal Articles

Outcomes and Prognostic Factors of the Alternative Regimens for Angioimmunoblastic T Cell Lymphoma: A Retrospective Study

Jiaqin Yan, Bingjie Wang, Yankui Wei, Shasha Zhang, Lei Zhang, Ling Li, Xin Li, Xiaorui Fu, Xinhua Wang, Zhenchang Sun, Xudong Zhang, Mingzhi Zhang

Blood (2024) 144 (Supplement 1): 6408.

https://doi.org/10.1182/blood-2024-206732

Published: 2024

Journal Articles

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Xin Li, Jia Wei, Dong-feng Zeng, Shu-nan Qi, Bingzong Li, Wei Guo, Li Wang, Yajun Li, Xudong Zhang, Yong Yang, Shukai Qiao, Yan Zeng, Yunfei Song, Jing-wen Wang, Jian-min Ma, Liang Wang

Blood (2024) 144 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2024-206489

Published: 2024

Journal Articles

Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy

Blood (2024) 144 (Supplement 1): 6458.

https://doi.org/10.1182/blood-2024-202107

Published: 2024

Journal Articles

Cytokine Patterns for Secondary HLH: Experiences from a Single Center

Xiaoyan Feng, Miaomiao Meng, Zhenchang Sun, Xudong Zhang, Lei Zhang, Mingzhi Zhang

Blood (2024) 144 (Supplement 1): 4375.

https://doi.org/10.1182/blood-2024-207671

Published: 2024

Journal Articles

CD19/BCMA Dual-Targeting Fastcar-T GC012F for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: An Update

Xinfeng Chen, Yu Ping, Ling Li, Lei Zhang, Xudong Zhang, Jianmin Huang, Jia Liu, Gui Li, Huan Shi, Jiaping He, Yi Liang, Lihong Weng, Wenjie Yin, Lianjun Shen, Wei William Cao, Wenling Li, Mingzhi Zhang, Yi Zhang

Blood (2023) 142 (Supplement 1): 6847.

https://doi.org/10.1182/blood-2023-185476

Published: 2023

Journal Articles

Phase I Clinical Study of PA3-17 Injection in Patients with Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma

Blood (2023) 142 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2023-178484

Published: 2023

Journal Articles

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

Fenghua Gao, Jing Liu, Jiesong Wang, Lihong Liu, Zhiming Li, Yuqin Song, Xudong Zhang, Hui Zhou, Xiuhua Sun, Wei Zhang, Bing Xu, Liping Su, Wen Shujuan, Rong Tao, Ou Bai, Qingyuan Zhang, Liqun Zou, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2023-174308

Published: 2023

Journal Articles

Efficacy and Safety of Chemotherapy (DDGP vs VIPD) Followed Radiotherapy Vs Radiotherapy Followed Chemotherapy (DDGP vs VIPD) Vs Radiotherapy Alone for Newly Diagnosed Early Stage Extranodal Natural Killer/T Cell Lymphoma: Final Results of a Prospective, Multicenter, Randomized, Controlled Clinical Trial

Mingzhi Zhang, Lei Zhang, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Yu Chang, Xudong Zhang, Hui Yu, Feifei Nan, Zhiyuan Zhou, Xiyang Liu, Xiaolong Wu, Liqun Zou, Hui Zhou, Hongwei Xue

Blood (2023) 142 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2023-188245

Published: 2023

Journal Articles

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Xudong Zhang, Wenhua Wang, Shanshan Ma, Mengke Fan, Linan Zhu, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Zhaoming Li, Jiaqin Yan, Mingzhi Zhang

Blood (2022) 140 (Supplement 1): 12075–12076.

https://doi.org/10.1182/blood-2022-159383

Published: 2022

Journal Articles

Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-137449

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Longitudinal ctdna tracking by low-pass whole-genome sequencing during CD19 CAR-T cell therapy for B-cell lymphomas

Tumor-associated macrophages (CD68+) as a potential prognostic biomarker for PD-1 inhibitor response in relapsed/refractory classical Hodgkin lymphoma

Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors

Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis

Selinexor combined with pegaspargase and dexamethasone, followed by radiotherapy, for newly diagnosed stage I–II natural killer/T-cell lymphoma: A multicenter, single-arm, Phase I/II study

Orelabrutinib plus anti-PD-1 antibody and fotemustine for newly diagnosed primary central nervous system lymphoma: Phase I/II results

Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Oligocentric castleman disease: Clinical characteristics and surgical outcomes from a single-centre retrospective study

POD 12 As a Robust Prognostic Index in Patients with Angioimmunoblastic T-Cell Lymphoma: A Single-Center Study

Outcomes and Prognostic Factors of the Alternative Regimens for Angioimmunoblastic T Cell Lymphoma: A Retrospective Study

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy

Cytokine Patterns for Secondary HLH: Experiences from a Single Center

CD19/BCMA Dual-Targeting Fastcar-T GC012F for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: An Update

Phase I Clinical Study of PA3-17 Injection in Patients with Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma

Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only